NCT01834950View on ClinicalTrials.gov

Identification of Early Markers of Response and Resistance to Trastuzumab

NACompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 27, 2013

Primary Completion Date

December 10, 2017

Study Completion Date

December 10, 2017

Conditions
Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer
Interventions
OTHER

Blood test

Trial Locations (1)

94805

Institut Gustave Roussy, Villejuif

All Listed Sponsors
collaborator

European Commission

OTHER

lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

NCT01834950 - Identification of Early Markers of Response and Resistance to Trastuzumab | Biotech Hunter | Biotech Hunter